Her2-neu: a target in lung cancer?

被引：12

作者：

Andre, F ^{[1
]}

Le Chevalier, T ^{[1
]}

Soria, JC ^{[1
]}

机构：

[1] Inst Gustave Roussy, Dept Med, Villejuif, France

来源：

ANNALS OF ONCOLOGY | 2004年 / 15卷 / 01期

关键词：

D O I：

10.1093/annonc/mdh033

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：3 / 4

页数：2

共 19 条

[1]

Bunn PA, 2001, CLIN CANCER RES, V7, P3239

[2] HER2 as a prognostic and predictive marker for breast cancer [J].

Cooke, T ;

Reeves, J ;

Lanigan, A ;

Stanton, P .

ANNALS OF ONCOLOGY, 2001, 12 :23-28

[3] ERBB-2 IS A POTENT ONCOGENE WHEN OVEREXPRESSED IN NIH/3T3 CELLS [J].

DIFIORE, PP ;

PIERCE, JH ;

KRAUS, MH ;

SEGATTO, O ;

KING, CR ;

AARONSON, SA .

SCIENCE, 1987, 237 (4811) :178-182

[4] Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer:: Evidence from a phase III randomized trial [J].

Ellis, MJ ;

Coop, A ;

Singh, B ;

Mauriac, L ;

Llombert-Cussac, A ;

Jänicke, F ;

Miller, WR ;

Evans, DB ;

Dugan, M ;

Brady, C ;

Quebe-Fehling, E ;

Borgs, M .

JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (18) :3808-3816

[5]

Fernandes A, 1999, INT J CANCER, V83, P564, DOI 10.1002/(SICI)1097-0215(19991112)83:4<564::AID-IJC20>3.0.CO

[6]

2-Q

[7]

GATZEMEIER U, 2004, IN PRESS ANN ONCOL, V15

[8] Pleural mesothelioma: combined modality treatments [J].

Giaccone, G .

ANNALS OF ONCOLOGY, 2002, 13 :217-225

[9] Evidence for epidermal growth factor receptor-enhanced chemosensitivity in combinations of cisplatin and the new irreversible tyrosine kinase inhibitor CI-1033 [J].

Gieseg, MA ;

de Bock, C ;

Ferguson, LR ;

Denny, WA .

ANTI-CANCER DRUGS, 2001, 12 (08) :683-690

[10] Prognostic value of immunohistochemical expressions of p53, HER-2/neu, and bcl-2 in stage I non-small-cell lung cancer [J].

Han, H ;

Landreneau, RJ ;

Santucci, TS ;

Tung, MY ;

Macherey, RS ;

Shackney, SE ;

Sturgis, CD ;

Raab, SS ;

Silverman, JF .

HUMAN PATHOLOGY, 2002, 33 (01) :105-110

← 1 2 →